WuXi Biologics stated that it is "steadily achieving" growth in both revenue and profit for the fiscal year 2025
According to a document from the Hong Kong Stock Exchange on January 11, WuXi Biologics will present at the annual healthcare conference, as the company steadily achieves its fiscal year 2025 goals of growth in both revenue and profit. The business growth momentum for fiscal year 2026 continues, supported by research services, drug development, and manufacturing operations. The research services business maintains the strong momentum from 2024 into 2025, with accelerated collaboration on CD3 TCE molecules, marking a strategic milestone for the platform. The total potential milestone payments for collaborative projects in 2025 could exceed USD 4 billion
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments